Who owns BridgeBio Pharma (BBIO)? Superinvestor holders

8 superinvestors of the 157 tracked here hold BridgeBio Pharma (BBIO) in their latest 13F filing, with $2.7B between them. Andrew Spokes gives it the most weight: 4.89% of the reported portfolio.

Hold it now
8
of 157 tracked
Combined value
$2.7B
Bought / sold
6 / 2
last quarter

Key facts

Superinvestors holding it
8 of 157
Biggest holder
Andrew Spokes, $937.5M
Largest weight
Andrew Spokes, 4.89%of their portfolio
Combined value
$2.7B
Bought last quarter
6
Sold last quarter
2

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding BBIO, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1Andrew SpokesFarallon Capital Management4.89%$937.5M14.25M▲ Added 33%+3.5MQ3 2026
2Andreas HalvorsenViking Global Investors2.11%$741M9.95M▼ Reduced 16%−1.89MQ2 2026
3John Overdeck and David Siegel (founders)Two Sigma Investments0.18%$240.8M3.66M▼ Reduced 22%−1.06MQ3 2026
4Steve CohenPoint72 Asset Management0.17%$113.6M1.53MNew+1.53MQ2 2026
5David Shaw (founder)D. E. Shaw & Co.0.17%$270.6M3.63M▲ Added 43%+1.09MQ2 2026
6Ken GriffinCitadel Advisors0.16%$280M3.76M▲ Added 18%+586.21KQ2 2026
7Ray Dalio (founder)Bridgewater Associates0.14%$33.4M448.14K▲ Added 73%+188.68KQ2 2026
8Primecap teamPrimecap Management0.07%$111.8M1.7M▲ Added 67%+683.45KQ3 2026

Quarter by quarter

Superinvestor ownership of BBIO by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 202692319.61M$1.3B21
Q2 2026157734.78M$2.6B61
Q1 2026157527.55M$2B41
Q4 2025157425.38M$1.9B22
Q3 2025157426.53M$1.4B22
Q2 2025157326.49M$1.1B22
Q1 2025156328.22M$975.7M22
Q4 2024156330.34M$832.5M10

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of BBIO held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Andrew Spokes14.25M10.74M9.37M9M8.19M7.9M5.73M4.2M
John Overdeck and David Siegel (founders)3.66M4.72M3.12M1.95M2.33M———
Primecap team1.7M———————
Andreas Halvorsen·9.95M11.84M14.39M15.98M18.56M22.06M25.12M
Ken Griffin·3.76M3.17M—————
David Shaw (founder)·3.63M——————
Steve Cohen·1.53M——————
Ray Dalio (founder)·448.14K——————
Polen Capital team——45.93K38.24K36.16K35.65K——
Stanley Druckenmiller·—————438.05K—
Zhang Lei·——————1.02M

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own BBIO?

In their latest 13F filings: Andrew Spokes (4.89% of the portfolio, $937.5M), Andreas Halvorsen (2.11% of the portfolio, $741M), John Overdeck and David Siegel (founders) (0.18% of the portfolio, $240.8M), Steve Cohen (0.17% of the portfolio, $113.6M), David Shaw (founder) (0.17% of the portfolio, $270.6M), Ken Griffin (0.16% of the portfolio, $280M), Ray Dalio (founder) (0.14% of the portfolio, $33.4M), Primecap team (0.07% of the portfolio, $111.8M).

Who bought BBIO last quarter?

Andrew Spokes (added 33%), Steve Cohen (new position), David Shaw (founder) (added 43%), Ken Griffin (added 18%), Ray Dalio (founder) (added 73%), Primecap team (added 67%). “Last quarter” is each investor's latest reported quarter.

Who sold BBIO last quarter?

Reduced: Andreas Halvorsen (16% fewer shares), John Overdeck and David Siegel (founders) (22% fewer shares).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns BridgeBio Pharma (BBIO)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/BBIO/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to BBIO by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.